A-286501

• CAT Number: I021081
• CAS Number: 483341-15-7
• Molecular Formula: C11H14BrN5O2
• Molecular Weight: 328.17
• Purity: 98%
• Synonyms: A-286501; A 286501; A286501.
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (1S,2R,3S,5R)-3-amino-5-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
• InChI: InChI=1S/C11H14BrN5O2/c12-4-2-17(6-1-5(13)8(18)9(6)19)11-7(4)10(14)15-3-16-11/h2-3,5-6,8-9,18-19H,1,13H2,(H2,14,15,16)/t5-,6+,8+,9-/m0/s1
• InChIKey: FKFYQPGMXTXSTC-LWIVVEGESA-N
• SMILES: BrC(C1=C2N=CN=C1N)=CN2[C@H]3[C@H](O)[C@H](O)[C@@H](N)C3

A-286501(CAT: I021081) is a novel, orally active adenosine kinase inhibitor that modulates adenosine metabolism by blocking the phosphorylation of adenosine to adenosine monophosphate (AMP). This inhibition increases extracellular adenosine levels, which can enhance adenosine receptor activation, leading to anti-inflammatory, neuroprotective, and cardioprotective effects. A-286501 is widely studied in pharmacology and therapeutic research for its potential in treating conditions such as chronic pain, epilepsy, ischemia-reperfusion injury, and inflammatory diseases. Its oral bioavailability and selectivity make it a valuable tool for understanding adenosine signaling and for developing therapies targeting adenosine-related pathways in various diseases.